Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has $6.00 target price on the specialty pharmaceutical company’s stock.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other analysts have also recently issued reports on ADMS. BidaskClub upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, February 25th. ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, April 1st. Needham & Company LLC cut Adamas Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, March 5th. Mizuho cut Adamas Pharmaceuticals from a neutral rating to an underperform rating and cut their target price for the stock from $11.00 to $5.00 in a research report on Tuesday, March 5th. Finally, Northland Securities reiterated a buy rating and set a $28.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, March 5th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $20.25.
NASDAQ:ADMS opened at $4.99 on Tuesday. The company has a debt-to-equity ratio of 2.00, a current ratio of 7.03 and a quick ratio of 6.86. Adamas Pharmaceuticals has a 12-month low of $4.93 and a 12-month high of $29.49. The stock has a market cap of $137.39 million, a P/E ratio of -1.02 and a beta of 1.35.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. The firm had revenue of $11.67 million during the quarter, compared to analysts’ expectations of $12.78 million. As a group, research analysts anticipate that Adamas Pharmaceuticals will post -3.87 EPS for the current year.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 6,319 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total transaction of $50,488.81. Following the completion of the transaction, the chief executive officer now owns 176,291 shares in the company, valued at approximately $1,408,565.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 8,361 shares of company stock valued at $66,816 in the last 90 days. 24.90% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADMS. Broadfin Capital LLC grew its holdings in Adamas Pharmaceuticals by 96.8% during the 4th quarter. Broadfin Capital LLC now owns 2,614,468 shares of the specialty pharmaceutical company’s stock valued at $22,328,000 after buying an additional 1,286,044 shares in the last quarter. Macquarie Group Ltd. grew its holdings in Adamas Pharmaceuticals by 51.7% during the 4th quarter. Macquarie Group Ltd. now owns 2,708,217 shares of the specialty pharmaceutical company’s stock valued at $23,128,000 after buying an additional 923,099 shares in the last quarter. Deltec Asset Management LLC grew its holdings in Adamas Pharmaceuticals by 127.4% during the 1st quarter. Deltec Asset Management LLC now owns 536,836 shares of the specialty pharmaceutical company’s stock valued at $3,817,000 after buying an additional 300,712 shares in the last quarter. Sectoral Asset Management Inc grew its holdings in Adamas Pharmaceuticals by 25.5% during the 4th quarter. Sectoral Asset Management Inc now owns 1,133,924 shares of the specialty pharmaceutical company’s stock valued at $9,684,000 after buying an additional 230,500 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Adamas Pharmaceuticals by 91.6% during the 4th quarter. Millennium Management LLC now owns 479,899 shares of the specialty pharmaceutical company’s stock valued at $4,098,000 after buying an additional 229,404 shares in the last quarter. Institutional investors and hedge funds own 84.76% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Recommended Story: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.